Cyclacel Pharmaceuticals (CYCC) Competitors $0.23 +0.01 (+4.48%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.22 -0.01 (-2.70%) As of 04/17/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCC vs. FRTX, NKGN, RNAZ, ALZN, AEZS, BCLI, SNGX, KLTO, NLSP, and SXTPShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Fresh Tracks Therapeutics (FRTX), NKGen Biotech (NKGN), TransCode Therapeutics (RNAZ), Alzamend Neuro (ALZN), Aeterna Zentaris (AEZS), Brainstorm Cell Therapeutics (BCLI), Soligenix (SNGX), Klotho Neurosciences (KLTO), NLS Pharmaceutics (NLSP), and 60 Degrees Pharmaceuticals (SXTP). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. Fresh Tracks Therapeutics NKGen Biotech TransCode Therapeutics Alzamend Neuro Aeterna Zentaris Brainstorm Cell Therapeutics Soligenix Klotho Neurosciences NLS Pharmaceutics 60 Degrees Pharmaceuticals Fresh Tracks Therapeutics (NASDAQ:FRTX) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, community ranking, media sentiment and institutional ownership. Does the media refer more to FRTX or CYCC? In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than Fresh Tracks Therapeutics. MarketBeat recorded 1 mentions for Cyclacel Pharmaceuticals and 0 mentions for Fresh Tracks Therapeutics. Fresh Tracks Therapeutics' average media sentiment score of 0.00 equaled Cyclacel Pharmaceuticals'average media sentiment score. Company Overall Sentiment Fresh Tracks Therapeutics Neutral Cyclacel Pharmaceuticals Neutral Which has more volatility & risk, FRTX or CYCC? Fresh Tracks Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500. Is FRTX or CYCC more profitable? Fresh Tracks Therapeutics has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -18,150.00%. Fresh Tracks Therapeutics' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Fresh Tracks TherapeuticsN/A N/A N/A Cyclacel Pharmaceuticals -18,150.00%-1,901.11%-188.23% Do analysts rate FRTX or CYCC? Cyclacel Pharmaceuticals has a consensus price target of $11.00, suggesting a potential upside of 4,765.10%. Given Cyclacel Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Cyclacel Pharmaceuticals is more favorable than Fresh Tracks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fresh Tracks Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals believe in FRTX or CYCC? 25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are owned by insiders. Comparatively, 68.0% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, FRTX or CYCC? Fresh Tracks Therapeutics has higher revenue and earnings than Cyclacel Pharmaceuticals. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFresh Tracks Therapeutics$10.06M0.56-$5.69M-$1.41-0.66Cyclacel Pharmaceuticals$74K633.50-$22.56M-$3.50-0.06 Does the MarketBeat Community favor FRTX or CYCC? Cyclacel Pharmaceuticals received 187 more outperform votes than Fresh Tracks Therapeutics when rated by MarketBeat users. Likewise, 45.17% of users gave Cyclacel Pharmaceuticals an outperform vote while only 0.00% of users gave Fresh Tracks Therapeutics an outperform vote. CompanyUnderperformOutperformFresh Tracks TherapeuticsOutperform VotesNo VotesUnderperform Votes1100.00% Cyclacel PharmaceuticalsOutperform Votes18745.17% Underperform Votes22754.83% SummaryCyclacel Pharmaceuticals beats Fresh Tracks Therapeutics on 9 of the 17 factors compared between the two stocks. Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.88M$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.026.8921.8017.78Price / Sales633.50231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.405.916.443.97Net Income-$22.56M$142.72M$3.21B$247.65M7 Day Performance-5.40%4.38%2.85%1.80%1 Month Performance-25.45%-12.76%-8.64%-6.98%1 Year Performance-87.78%-9.69%11.38%1.34% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals2.0176 of 5 stars$0.23+4.5%$11.00+4,765.1%-88.4%$46.88M$74,000.00-0.0214Analyst ForecastNews CoverageGap DownFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+3.0%$5.59M$10.06M-0.6620NKGNNKGen BiotechN/A$0.12+4.3%N/A-87.6%$5.40M$80,000.00-0.02N/AGap UpRNAZTransCode Therapeutics2.0311 of 5 stars$0.41+1.5%$20.00+4,778.0%-100.0%$5.37MN/A0.009Analyst ForecastAnalyst RevisionNews CoveragePositive NewsALZNAlzamend Neuro2.1995 of 5 stars$0.79+2.8%$20.00+2,434.9%-90.7%$5.22MN/A0.004Short Interest ↑Gap UpAEZSAeterna ZentarisN/A$2.85+1.6%N/A-64.4%$5.11M$2.37M-0.1920Analyst ForecastBCLIBrainstorm Cell Therapeutics3.3151 of 5 stars$0.78+1.8%$30.00+3,765.5%-89.2%$5.06MN/A-0.1640SNGXSoligenix1.4839 of 5 stars$1.96-9.7%N/A-74.3%$4.92M$840,000.00-0.2620Short Interest ↓Gap UpHigh Trading VolumeKLTOKlotho NeurosciencesN/A$0.17+2.4%N/AN/A$4.87MN/A0.00N/ANLSPNLS PharmaceuticsN/A$1.45+7.4%N/A+997.7%$4.86MN/A0.006Short Interest ↓Positive NewsGap UpSXTP60 Degrees Pharmaceuticals1.0532 of 5 stars$3.26+10.1%N/A+151.0%$4.80M$607,574.00-0.323Short Interest ↓ Related Companies and Tools Related Companies Fresh Tracks Therapeutics Competitors NKGen Biotech Competitors TransCode Therapeutics Competitors Alzamend Neuro Competitors Aeterna Zentaris Competitors Brainstorm Cell Therapeutics Competitors Soligenix Competitors Klotho Neurosciences Competitors NLS Pharmaceutics Competitors 60 Degrees Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCC) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYCC Stock Free CYCC Stock Alerts